Ainos, Inc. (NASDAQ:AIMD, AIMDW), a healthcare company specializing in AI-powered point-of-care testing and therapeutics, has reported significant progress in the clinical trials of its "Ainos Flora" device, which utilizes AI Nose technology for rapid detection of infections. The device, currently being tested at four major medical centers in Taiwan, has completed 75 clinical cases, providing valuable data for the development of the next-generation product.
The Ainos Flora device is designed for non-invasive detection of bacterial, fungal, and sexually transmitted infections in women. The company announced that the AI algorithm model has shown improved accuracy by integrating more real-world data into the Ainos AI model. The use of advanced data processing techniques has enhanced the device's reliability by addressing individual and environmental variations.
Ainos is developing an upgraded version of Ainos Flora, incorporating NVIDIA (NASDAQ:NVDA) CUDA technology to expand its testing capabilities to include viral infections. The next-gen device is tailored for at-home testing, allowing users to obtain accurate results without professional medical assistance. The design and laboratory testing phase is expected to conclude in the third quarter, with clinical trials slated to begin in the fourth quarter.
Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and CEO of Ainos, highlighted the need for accessible and rapid testing solutions for vaginal health and STIs, especially given the high rate of new STI cases among young adults in the U.S. The company aims to address this need with Ainos Flora, which is positioned in a market projected to reach US$256 billion by 2028.
Ainos' commitment to innovation is evident in its portfolio of over 50 approved and pending patents, focusing on integrating AI with digital nose sensors for diagnostic tools.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.